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MiR-17–92 Cluster-Enriched Exosomes Derived
from Human Bone Marrow Mesenchymal Stromal Cells
Improve Tissue and Functional Recovery in Rats
after Traumatic Brain Injury
Yanlu Zhang,1 Yi Zhang,2 Michael Chopp,2,3 Haiyan Pang,1 Zheng Gang Zhang,2
Asim Mahmood,1 and Ye Xiong1,*
Abstract
Exosomes play an important role in intercellular communication by delivering microribonucleic acids
(miRNAs) to recipient cells. Previous studies have demonstrated that multi-potent mesenchymal stromal
cell (MSC)-derived exosomes improve functional recovery after experimental traumatic brain injury (TBI).
This study was performed to determine efﬁcacy of miR-17-92 cluster-enriched exosomes (Exo-17-92) harvested from human bone marrow MSCs transfected with a miR-17-92 cluster plasmid in enhancing tissue
and neurological recovery compared with exosomes derived from MSCs transfected with an empty plasmid
vector (Exo-empty) for treatment of TBI. Adult male rats underwent a unilateral moderate cortical contusion. Animals received a single intravenous injection of miR-17-92 cluster-enriched exosomes (100 lg/rat,
approximately 3.75x1011 particles, Exo-17-92) or control exosomes (100 lg/rat, Exo-empty) or Vehicle
(phosphate-buffered solution) one day after injury. A battery of neurological functional tests was performed
weekly after TBI for ﬁve weeks. Spatial learning and memory were measured on days 31–35 after TBI using
the Morris water maze test. All animals were sacriﬁced ﬁve weeks after injury. Their brains were processed
for histopathological and immunohistochemical analyses of lesion volume, cell loss, angiogenesis, neurogenesis, and neuroinﬂammation. Compared with Vehicle, both Exo-17-92 and Exo-empty treatments significantly improved sensorimotor and cognitive function, reduced neuroinﬂammation and hippocampal
neuronal cell loss, promoted angiogenesis and neurogenesis without altering the lesion volume. Moreover,
Exo-17-92 treatment exhibited a signiﬁcantly more robust therapeutic effect on improvement in functional
recovery by reducing neuroinﬂammation and cell loss, enhancing angiogenesis and neurogenesis than did
Exo-empty treatment. Exosomes enriched with miR-17-92 cluster have a signiﬁcantly better effect on improving functional recovery after TBI compared with Exo-empty, likely by reducing neuroinﬂammation
and enhancing endogenous angiogenesis and neurogenesis. Engineering speciﬁc miRNA in exosomes
may provide a novel therapeutic strategy for management of unilateral moderate cortical contusion TBI.
Keywords: exosomes; functional outcome; microRNA; neuroinﬂammation; neuroplasticity; traumatic brain injury

Introduction
Traumatic brain injury (TBI) is a major public health
problem worldwide.1 A TBI is a very complex injury,
and currently there is no effective therapy for improving
functional recovery identified from clinical TBI trials.2

Cell therapies have emerged as a potential management
option for TBI.3–6 There are some concerns regarding
the use of embryonic and fetal stem cells and induced
pluripotent stem cells from somatic cells, particularly in
terms of risks for immune rejection and tumorigenicity.7
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Multi-potent mesenchymal stromal/stem cells (MSC)
have emerged as a promising candidate for cell therapy.4–6,8 The MSCs are self-renewing stem/progenitor
cells that exist in bone marrow, adipose tissue, blood, and
many other organs.9 Previous studies show that some of
the transplanted MSCs migrate into injured brain but
only a fraction of them display neural cell-like markers.10,11 These data indicate that MSC treatment-induced
functional recovery is not directly linked to neural differentiation of the transplanted MSCs.
Increasing evidence suggests that MSC-induced functional recovery is associated with their release of exosomes.12–14 Exosomes are a subtype of the extracellular
vesicles that are delimited by a lipid bilayer and released from cells; they are small particles of endocytic
origin with a diameter of 30–150 nm.15,16 Exosome
cargo (e.g., ribonucleic acid [RNA], deoxyribonucleic
acid [DNA], and proteins/enzymes) is protected from extracellular RNAase and other digestive enzymes and can
be effectively transferred to recipient cells.13 In contrast to MSCs, nano-sized exosomes can easily cross
the blood–brain barrier (BBB) and deliver their cargo
to neural cells,17 without cell transplant-induced vascular
obstructive effect and risks of tumorigenicity.18
The MSC-derived exosomes significantly improve
functional recovery in rodents19,20 and pigs21 after TBI
and in a monkey model of cortical injury.22 The mechanisms underlying the effects of MSC-derived exosomes
on improvement of functional recovery after TBI remain elusive. However, the MSC-derived exosomes
transfer their therapeutic factors, especially microRNAs
(miRNAs), to recipient cells, and therein regulate gene
expression, mediate biological function, and promote
therapeutic response.13,23 The miRNAs are singlestranded and noncoding RNAs with approximately 22
nucleotides, typically by binding to the 3’ untranslated
region (3’-UTR) of the complementary mRNA sequence, resulting in translational repression and gene
silencing.24,25
A single miRNA can bind to hundreds of different
transcripts, and miRNAs may regulate up to 60% of the
protein-coding genes in the human genome.26,27 Therefore, a miRNA transferred by exosomes can regulate
multiple cellular signaling pathways in the recipient
cell, and exosomal miRNAs are considered as an alternative mediator of intercellular communication.26
Our previous work demonstrates that MSC-derived
exosomes enriched with the multi-functional miR-17-92
cluster enhance axonal growth of cultured cortical neurons28 and improve neurovascular remodeling and functional recovery in ischemic stroke rats.29 The present
study was designed to determine the therapeutic effects
of MSC-derived exosomes enriched with miR-17-92
cluster on amplifying brain repair and improving functional recovery in a clinically relevant model of TBI.
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Methods
Animals
The use of young male Wistar rats (2–3 months, Charles
River, Wilmington, MA) in this study was approved by
the Henry Ford Health System Institutional Animal
Care and Use Committee. The rigorous clinical trial design (randomization, placebo controlled, and blinding)
to pre-clinical TBI with a clinically relevant treatment
scheme has been employed.30,31 The persons who performed the experiments, collected data, and assessed outcome
were blinded during the experiments (see Supplementary
Data for details).
Generation and characterization
of engineered exosomes carrying the elevated
miR-17-92 cluster
Human MSCs (hMSCs) were expanded (Theradigm,
Bethesda, MD). The method is essentially as described.32
Briefly, hMSCs at passage 5 were plated and cultured in
a-Minimum Essential Media (a-MEM, Thermo Fisher
Scientific, Waltham, MA).33 To generate tailored exosomes with elevated miR-17-92 cluster, hMSCs were
transfected with a miR-17-92 cluster plasmid (pCAGGFP-miR-17-92) or an empty vector according to our
published protocol.28,34
The following primers were used for amplification:
forward, 5¢-CGGAATTCGTCAGGATAATGTCAAAG
TGCTTACA; and reverse, CGGGTACCACCAAACTC
AACAGGCCG, with EcoRI and KpnI at 5¢ ends.
A pCAG-green fluorescent protein (GFP)-miR-17-92
cluster vector was constructed by cloning the primary
miR-17–92 cluster fragment into the EcoRI and KpnI
sites in the pCAG-GFP vector (Addgene plasmid
11150).35 The pCAG-GFP-miR-17-92 vector (2 lg) was
introduced into cultured hMSCs by electroporation
using a Nucleofector kit (Mirus). An empty pCAGGFP vector was used as a negative control.
For the exosome isolation, when the cells reached
60–80% confluence, conventional culture medium was
replaced with an exosome-depleted fetal bovine serumcontained medium (EXO-FBS-250 A-1, System Biosciences, Mountain View, CA), and the hMSCs were
cultured for an additional 48 h.19 The supernatant of cultured hMSCs was collected and passed through a 0.22 lm
filter (Millipore, Temecula, CA) to remove dead cells and
large growth debris. The filtered supernatant was run at
10,000 · g for 30 min. The supernatant was collected
and run at 100,000 · g for 3 h to collect the exosomes,
as described in our previous study.28 The supernatant
was then collected as a negative control. The pellet was
diluted with sterilized phosphate-buffered saline (PBS)
for further characterization and experimental treatments.
Nanoparticle tracking analysis with the NanoSight
instrument was used to measure numbers and sizes of
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particles in the exosome-enriched pellets according to
the manufacturer’s instructions (Merkel Technologies,
Yehud, Israel). The size of exosomes was further verified
by transmission electron microscopy (TEM, Philips
EM208) image, as described in our previous study.14
Isolated exosomes were identified using Western blot
analysis of exosomal markers (Alix and Hsp70). The exosomal protein concentration was measured with the micro
Bicinchoninic Acid protocol (Pierce, Rockford, IL).
Please see Methods in the Supplementary Data for details
(Supplementary Fig. S1).
TBI model
A controlled cortical impact (CCI) model of TBI was
employed in the present study.36 The CCI-TBI model
is described in our previous study.37 In brief, rats were
anesthetized with ketamine/xylazine (100/10 mg/kg) intraperitoneally (IP) and placed in a stereotactic frame.
A 10-mm-diameter craniotomy was performed over the
parietal cortex, and the dura mater was kept. THE CCI
was delivered with a pneumatic piston (6-mm tip in
diameter, 4 m/sec velocity, and 2.5 mm depth).19,37 This
moderate TBI causes consistent cortical tissue loss
(lesion cavity) and significant neuronal damage in the
ipsilateral hippocampus with sensorimotor and cognitive
deficits manifested.2,37
Animal groups
To determine the effect of exosomes enriched with the
miR-17-92 cluster on TBI rats, we randomly divided
TBI rats into one of the three groups: (1) TBI + Vehicle
(PBS, n = 8), (2) TBI + Exo-empty (exosomes derived
from human MSCs transfected with an empty vector,
n = 8), and (3) TBI + Exo-17-92 (exosomes from human
MSCs with enriched miR-17-92 cluster, n = 8). Exosomes
(100 lg proteins, approximately 3.75 · 1011 particles,
0.5 mL in PBS/rat, n = 8) were administered via tail
vein to rats starting at 24 h after TBI. Rats treated with
Vehicle (0.5 mL PBS) were used as a treatment control
(Vehicle group). Rats with sham surgery without TBI/
treatment were used as a TBI control (Sham group).
The administration dose and time were chosen based
on our previous dose-response and window study of exosomes in TBI rats.37 5-bromo-2’-deoxyuridine (BrdU,
100 mg/kg) was injected IP into rats starting one day
after TBI, once daily for seven days, to label proliferating
cells in the brain.37
Behavioral tests
Primary end-points included the Morris water maze
(MWM) test performed at 31–35 days after TBI, and a
battery of sensorimotor tests including modified neurological severity score (mNSS), footfault, and adhesive
removal performed at one day and then weekly up to
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35 days after TBI. These neurological outcome measurements were performed based on our published protocol.19,37 We employed a modified MWM test that uses
the concept of probe trial because the hidden platform locations in the correct quadrant change for each trial.38 For
details, please see Methods in the Supplementary Data.
Histology and immunostaining
Anesthetized animals were sacrificed for collecting of
brains 35 days after TBI. Secondary end-points included
neuronal cell loss, lesion volume, angiogenesis, neurogenesis, and neuroinflammation. In brief, brains after
transcardial perfusion and fixation in paraformaldehyde
were embedded in paraffin and a series of 6-lm-thick
slides were prepared. The cortical lesion volume was measured according to our published protocol.37 In brief, lesion volume (mm3) was calculated by measuring the area
of the lesion (mm2) and then by multiplying the sum of
the lesioned areas obtained from each section by the distance between sections (mm) identified by comparing
each hematoxylin and eosin section with the Rat Brain
in Stereotaxic Coordinates by Paximos and Watson,
and expressed as a percent of the contralateral (noninjured) hemisphere.37 Glial fibrillary acidic protein (GFAP,
marker for astrocytes), CD 68- (marker for microglia/
macrophages), and neuronal nuclei (NeuN, for neurons)immunostainings were performed and counted according to our published methods32,37 and described in the
Supplementary Data.
Immunoﬂuorescent staining
Newly generated endothelial cells and newborn mature
neurons 35 days after TBI were identified by double labeling for BrdU with endothelial barrier antigen (EBA)
or neuronal nuclei (NeuN), respectively.19,37 The EBA+
endothelial cells, CD68+ microglia/macrophages, GFAP+
astrocytes, EBA+/BrdU+ cells were counted in the dentate gyrus (DG) and lesion boundary zone (LBZ).19 The
LBZ is defined as the region of cortical tissue between
the lesion cavity and the intact tissue.37 The NeuN/
BrdU-colabeled cells in the subgranular zone and
granular cell layer of the DG were counted for analysis
of neurogenesis.
The images in the regions of interest were acquired at a
magnification of either 200 or 400 under the microscope
(Nikon, Eclipse 80i) using CoolSNAP color camera
(Photometrics) and analyzed with MetaMorph image
analysis system (Molecular Devices). In brief, five fields
of view in the LBZ from the epicenter of the injury cavity
(bregma 3.3 mm), and nine fields of view in the ipsilateral DG were counted in each section according to our
published method.37 A Zeiss LSM 510 META confocal laser scanning microscope connected to a personal
computer running the Zeiss LSM Image Software was
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employed to verify colocalization of BrdU with NeuN
in the DG. For details, please see the Supplementary
Data (Supplementary Fig. S2).
Cell counting and quantitation
In the present study, we did not use stereological quantification methods because immunoreactive positive cells
in the present study are not homogenously distributed
and the data of interest are relative difference and not absolute value. All counting was performed on a computer
monitor to improve visualization and in one focal plane
to avoid oversampling. The methods employed to count
cells have been utilized in our previous studies.37 Please
see detailed description of cell counting and quantitation
in the Supplementary Data.
Statistical analysis
Data presented as the means with standard deviations
were tested for normality. Ranked data or a nonparametric Kruskal-Wallis test was used to analyze data if they
were not normally distributed. Data on repeated measurements of spatial performance and sensorimotor function
were analyzed with analysis of variance (ANOVA). Oneway ANOVA followed by post hoc Tukey tests was
used to compare the differences in cell counting between
the exosome-treated, Vehicle-treated and Sham groups.
A p value <0.05 was considered significant.
Results
Identiﬁcation of exosomes from hMSC
culture medium
Using a qNano nanopore-based exosome detection
system, we demonstrated that the size of hMSC-derived
exosomes is consistent with that measured with the transmission electron microscopy (see Supplementary Data
Fig. S1A). Western blots confirmed that exosomes contained high levels of exosome protein markers Alix and
Hsp70 compared with the supernatant (See Supplementary Data Fig. S1B). There were no significant differences
of exosomal characterization between Exo-17-92 and
Exo-empty. The quantitative reverse transcription polymerase chain reaction (qRT-PCR) data show that levels
of each member of miR-17-92 cluster (Supplementary
Materials Fig. S1C, p < 0.05) were significantly higher
in Exo-17-92 than in Exo-empty.
CCI-TBI model
A total of 24 TBI animals and eight sham animals were
included into the study. No animal died during the 35day study period. Moderate TBI was induced in this
study based on the CCI injury parameters and functional
test results.37,39 No differences in the mNSS, adhesive
removal, and footfault scores were detected 24 h postinjury among the three TBI groups (Fig. 1, p > 0.05).
The lack of significant differences in these functional

FIG. 1. Treatment with exosomes derived from
mesenchymal stem cells (MSCs) signiﬁcantly
improves neurological functional recovery
measured by the modiﬁed neurological severity
score (mNSS) (A), footfault test (B) and adhesive
removal test (C) in rats after traumatic brain injury
(TBI). Both Exo-empty and Exo-17-92 treatments
administered intravenously 24 h after TBI
signiﬁcantly reduced sensorimotor deﬁcits starting
at seven days post-injury compared with Vehicle
treatment. Compared with the Exo-empty, Exo-1792 exhibited signiﬁcantly better effects on
functional recovery. Data represent
mean – standard deviation. N = 8/group. Color
image is available online.
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tests indicates that all TBI animals had equivalent severity injury before study treatments (Vehicle, Exo-empty,
or Exo-17-92).
MiR-17-92 enriched exosomes improve
sensorimotor functional recovery
in rats after TBI
We generated hMSC-derived exosomes carrying elevated miR-17-92 cluster (Exo-17-92). We then treated
TBI rats intravenously (IV) 24 h post-injury with Exo17-92, or with control exosomes from MSCs transfected
with an empty vector (Exo-empty), or with Vehicle
(PBS). Compared with the Vehicle treatment, both Exoempty and Exo-17-92 treatments initiated 24 h post-TBI
significantly improved sensorimotor recovery measured
using mNSS (Fig. 1A), right forelimb footfault (Fig. 1B),
and adhesive removal (Fig. 1C) tests starting at day 7
post-TBI and lasting up to 35 days.
Importantly, at 35 days post-TBI, compared with Exoempty treatment, Exo-17-92 significantly reduced the
mNSS score (a decrease by 63% for Exo-empty vs.
77% for Exo-17-92, Fig. 1A, p < 0.05), the number of
right forelimb footfault (a decrease by 48% for Exoempty vs. 65% for Exo-17-92, Fig. 1B, p < 0.05), and
adhesive removal time (a decrease by 21% for Exoempty vs. 58% for Exo-17-92, Fig. 1C, p < 0.05).
MiR-17-92 enriched exosomes improve spatial
learning and memory
The MWM test is used for evaluating spatial learning and
memory in rodents40 The MWM test demonstrated that
TBI caused spatial learning deficits in rats after TBI.
Compared with the Vehicle group, both exosome treatments significantly reduced the time (latency, Fig. 2A,
p < 0.05) for animals to reach the hidden platform in the
water maze and increased the % of time spent in the correct quadrant (Fig. 2B, p < 0.05), indicating that exosomes
significantly improved spatial learning and memory in rats
after TBI. Post hoc Tukey testing demonstrated that there
was a statistically significant improved therapeutic effect
on reducing latency and increasing % of time spent in
the correct quadrant with Exo-17-92 treatment than with
the Exo-empty treatment at day 33–35 ( p < 0.05).
Collectively, our data demonstrate that both Exoempty and Exo-17-92 treatments administered IV 24 h
after TBI improved sensorimotor and cognitive functional
outcomes at day 33–35. Compared with the Exo-empty
treated rats, Exo-17-92 treated rats exhibited significantly
improved effects on TBI functional recovery.
MiR-17-92 enriched exosomes reduce
hippocampal neuronal cell loss in rats after TBI
Compared with the Vehicle treatment, exosome treatments significantly reduced the NeuN+ neuronal cell

FIG. 2. Treatment with exosomes derived from
mesenchymal stem cells (MSCs) signiﬁcantly
improves spatial learning and memory in the
Morris water maze (MWM) test measured by
latency to ﬁnd the hidden platform in the
correct quadrant by rats after traumatic brain
injury (TBI). Both Exo-empty and Exo-17-92
treatments administered intravenously 24 h after
TBI reduced the latency to reach the hidden
platform starting at 33 days (A) and increasing
the percentage of time spent in the correct
quadrant where the hidden platform was
located (B) in the MWM testing compared with
Vehicle treatment. Compared with the Exoempty, Exo-17-92 exhibited signiﬁcantly better
effects on reducing the latency and increasing
the percentage of time (A and B). Data
represent mean – standard deviation.
N = 8/group. Color image is available online.

loss in the DG (Fig. 3A–D, F3,28 = 302.98, p < 0.05) and
CA3 region (Fig. 3E–H, F3,28 = 51.94, p < 0.05) detected
at day 35 post-injury. A statistically significant effect
with exosomes on reducing neuronal cell loss was
found in the DG (Fig. 3I, Exo-empty vs. Vehicle, Exo17-92 vs. Vehicle, p < 0.05). There was a significant increase in neuronal cell number in the CA3 between the
two exosome treatment groups with a better effect from
Exo-17-92 treatment (Fig. 3I, Exo-17-92 v.s Exoempty, p < 0.05).
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FIG. 3. Treatment with exosomes signiﬁcantly reduces hippocampal neuronal cell loss after traumatic
brain injury (TBI). Neuronal nuclei (NeuN) staining was performed for detection of mature neurons at day 35
after TBI in the dentate gyrus (DG) region (A–D) and CA3 region (E-–H). Both Exo-empty and Exo-17-92
treatments administered intravenously 24 h after TBI reduced the NeuN+ cell loss in the DG (C and D) and
CA3 region (G and H) compared with Vehicle treatment (B and F). Compared with the Exo-empty (C and G),
Exo-17-92 exhibited signiﬁcantly better effects on reducing the neuronal cell loss in the DG region (D) and CA 3
region (H). Scale bars = 100 lm (H). Quantitative data shown in bar graph (I) represent mean – SD.
N = 8/group. Color image is available online.

MiR-17-92 enriched exosomes increase
angiogenesis in rats after TBI
Exosome treatments significantly increased angiogenesis
identified by EBA/BrdU+ double labeling for newborn
endothelial cells in the LBZ and DG compared with the
Vehicle treatment (Fig. 4A–E, p < 0.05). A significant increase in angiogenesis in the LBZ (Fig. 4E, F3,28 =
137.99, p < 0.001) and DG (Fig. 4E, F3,28 = 138.90,
p < 0.001) was detected in the Exo-17-92 group compared
with the Exo-empty group.

MiR-17-92 enriched exosomes increase
neurogenesis in the DG in rats after TBI
The TBI significantly increased the number of newborn
mature neurons in the DG of the ipsilateral hemisphere
compared with Sham controls measured at day 35 postinjury (Fig. 5A,B, F3,28 = 195.04, p < 0.001). Exosome
treatments, however, significantly increased the number
of newborn neurons compared with the Vehicle treatment
(Fig. 5B,C, p < 0.01). A significant increase in newly generated neurons was detected by measuring the number
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FIG. 4. Treatment with exosomes signiﬁcantly increases angiogenesis after traumatic brain injury (TBI).
5-bromo-2’-deoxyuridine/endothelial barrier antigen (BrdU/EBA+) staining was performed for detection of
newly generated endothelial cells at day 35 after TBI in the cortex and dentate gyrus (DG). Representative
images (A–D) from the ipsilateral cortex show BrdU+ (red) /EBA+ (green) newborn endothelial cells (white
arrows). Both Exo-empty (C) and Exo-17-92 (D) treatments administered intravenously 24 h after TBI
promoted angiogenesis in the cortex compared with Vehicle treatment (B). Compared with the Exo-empty,
Exo-17-92 exhibited signiﬁcantly better effects on increasing angiogenesis in the cortex and DG (E). Scale
bars = 100 lm (D). Quantitative data shown in bar graph (E) represent mean – standard deviation.
N = 8/group. Color image is available online.

of BrdU and NeuN positive cells in the Exo-17-92 group
compared with the Exo-empty group (Fig. 5C,D,
p < 0.05). Colocalization of BrdU with NeuN (Fig. 5A–E)
was further verified using a Zeiss LSM 510 META confocal laser scanning microscope (Fig. 5F and Supplementary Fig. S3).
MiR-17-92 enriched exosomes reduce brain
inﬂammation in rats after TBI
The TBI significantly increased the density of CD68+
macrophages/microglia in the LBZ (Fig. 6A,B, F3,28 =
388.85, p < 0.01) and DG (Fig. 6E,F, F3,28 = 73.07,
p < 0.01) of the ipsilateral hemisphere compared with
Sham controls. Exosome treatments significantly reduced
the CD68+ cell density in the LBZ (Fig. 6C,D) and

DG (Fig. 6G,H) compared with the Vehicle treatment
(Fig. 6B–F, p < 0.01). Compared with the Exo-empty
group, the Exo-17-92 group exhibited significantly reduced CD68+ cell number in the LBZ and DG region
(Fig. 6I, p < 0.01).
The TBI also significantly increased the number of
GFAP+ astrocytes in the LBZ (Fig. 7A,B, F3,28 = 44.85,
p < 0.001) and DG (Fig. 7E,F, F3,28 = 57.12, p < 0.001)
compared with Sham controls (Fig. 7A, 7E). Exosome
treatments significantly reduced the GFAP+ astrocyte
density in the LBZ (Fig. 7A–C) and DG (Fig. 7G,H) compared with the Vehicle treatment (Fig. 7B, 7F, p < 0.01).
The Exo-17-92 treatment group exhibited significantly
reduced GFAP+ cell number compared with the Exoempty treatment group (Fig. 7I, p < 0.05).
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FIG. 5. Treatment with exosomes signiﬁcantly increases neurogenesis 35 days after traumatic brain injury
(TBI). Double staining with 5-bromo-2’-deoxyuridine (BrdU, red)/neuronal nuclei (NeuN, green) was
performed to identify newborn mature neurons in the dentate gyrus (DG, A–D, white arrows). Scale
bar = 25 lm. Scale bars = 25 lm. Quantitative data shown in bar graphs (E) represent mean – standard
deviaion. N = 8/group. Colocalization between BrdU and NeuN in the DG was further veriﬁed using a Zeiss
LSM 510 META confocal laser scanning microscope (F). Color image is available online.

MiR-17-92 enriched exosomes do not alter
the volume of total brain tissue loss
in rats after TBI
No significant differences in the lesion volume were
observed 35 days post-injury (Fig. 8, F2,21 = 0.89, p =
0.427) between exosome and Vehicle treatment groups,
indicating that delayed (24 h post-injury) treatments
with exosomes do not alter cortical lesion volume.
Discussion
In the present study, we generated human bone marrow
MSC-derived exosomes carrying elevated miR-17-92
cluster (Exo-17-92) or control exosomes derived from
MSCs transfected with empty vector (Exo-empty).
Both Exo-empty and Exo-17-92 treatments administered IV 24 h in rats after moderate TBI improved sensorimotor and cognitive functional outcomes starting at
seven days post-injury that persisted to at least 35 days
post-injury compared with treatment control (Vehicle).
More importantly, compared with the Exo-empty,
TBI rats treated with Exo-17-92 exhibited significantly improved effects on both tissue and functional
recovery.
Specifically, compared with the Vehicle treatment, IV
administration of MSC-derived exosomes with or without enrichment of the miRNA-17-92 cluster significantly:

(1) increases the number of BrdU+/NeuN+ newborn
mature neurons in the DG (neurogenesis); (2) increases
the number of BrdU+/EBA+ newborn endothelial cells
in the LBZ and in the DG (angiogenesis); (3) reduces
neuronal cell loss in the CA3 and in the DG (neuroprotection); and (4) reduces the number of CD68+ microglia/
macrophages and GFAP+ astrocytes in the LBZ and
DG (anti-neuroinflammation).
These beneficial effects, in concert, may contribute to
significant improvement in sensorimotor and cognitive
functional recovery. Further, the levels of neuroprotection and neurorestoration are significantly enhanced in
the Exo-17-92 group compared with the Exo-empty
group. These data suggest that exosomes engineered to
carry select miRNAs may represent a novel approach
for management of TBI.
Our data showed that post-traumatic IV administration
of exosomes had no effects on lesion volume but reduced
hippocampal neuronal cell loss. These findings agree
with previous studies showing that delayed (24 h postinjury) treatment regimens confer functional improvement and hippocampal neural protection after TBI without significant reduction in cortical lesion volume.37,41,42
A recent study, however, demonstrated that early (one
hour post-injury) IV administration of a single dose of exosomes was able to reduce brain lesion sizes in a swine
model of severe TBI and hemorrhagic shock.43
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FIG. 6. Treatment with exosomes signiﬁcantly reduces the number of activated microglia/macrophages
after traumatic brain injury (TBI). CD68 staining was performed to identify activated microglia/macrophages
in the cortex (A–D) and dentate gyrus (DG) region (E–H). Both Exo-empty (C and G) and Exo-17-92 (D and
H) treatments administered intravenously 24 h after TBI reduced CD68+ microglia/macrophages compared
with Vehicle treatment (B and F). Compared with the Exo-empty, Exo-17-92 exhibited signiﬁcantly better
effects on reducing the number of CD68+ cells. Scale bars = 100 lm (H). Quantitative data shown in bar
graph (I) represent mean – standard deviation. N = 8/group. Color image is available online.

It is known that CCI-induced moderate TBI causes
focal cell death predominantly in the cerebral cortex
while delayed cell death occurs in the perilesional regions
including the hippocampus.44 It is likely that the delayed
treatment with exosomes administered 24 h post-injury
may not prevent severely damaged cells from death in
the injured cortex while delayed neuronal loss in the hippocampus develops slower and provides a longer therapeutic window for treatment.
The MSCs are multi-potent stromal cells that can be
isolated from virtually any adult tissue, self-renew, and
differentiate into a variety of cell types including the
osteogenic, adipogenic, chondrogenic, and neural line-

ages.45,46 Exogenously administered MSCs can migrate
to injured sites of TBI.5,47 In addition to their soluble factors and immunomodulatory effects, therapeutic effects
of MSCs for TBI may be attributed to their robust generation and release of exosomes.12 The use of MSC-derived
exosomes, as an alternative to MSCs, confers several
advantages including their ability to cross biological barriers and lack of complications that arise from stem cellinduced ectopic tumor formation, entrapment in lung microvasculature, and immune rejection.12,48,49
Intravenous administration of cell-free MSCgenerated exosomes improves functional recovery after
TBI in rats,19,20,32,50 pigs,21 and monkeys.22 The
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FIG. 7. Treatment with exosomes signiﬁcantly reduces the number of astrocytes after traumatic brain
injury (TBI). Glial ﬁbrillary acidic protein (GFAP) staining was performed to identify astrocytes in the cortex
(A–D) and dentate gyrus (DG) region (E–H). Both Exo-empty (C and G) and Exo-17-92 (D and H) treatments
administered intravenously 24 h after TBI reduced GFAP+ astrocytes compared with Vehicle treatment
(B and F). Compared with the Exo-empty, Exo-17-92 exhibited signiﬁcantly better effects on reducing the
number of GFAP+ cells. Scale bars = 100 lm (H). Quantitative data shown in bar graph (I) represent
mean – standard deviation. N = 8/group. Color image is available online.

beneficial effects of exosome treatments for brain injury
are attributed to: reduction of neuronal loss and neuroinflammation, enhancement in angiogenesis and neurogenesis,51 improvement in BBB integrity and neuroprotection
and reduction in brain edema.52 The precise mechanisms
of exosome therapeutic effects on functional recovery
after TBI are not fully understood.
Exosomes contain complex molecular cargos.53,54 The
benefit and potential strength of exosome treatment, as
with stem cell therapy, result from targeting multiple injury and repair mechanisms mediated by delivery of exosomal complex cargos to recipient cells. Intravenously

administered exosomes can incorporate into recipient parenchymal cells in rats with stroke55 and TBI.12
A single miRNA can regulate expression of many
genes at the post-transcriptional level.56 Exosomal
miRNAs play an important role in intercellular communication in neurological injuries.12,23,57 Exosome therapy
may transfer miRNA to elicit a multi-targeted effect,
rather than the traditional, single molecular pathway
approach for treatment of TBI.12,13,23 Thus, exosomes
provide a novel multi-factorial therapeutic approach
capitalizing on the benefits of MSCs without having to
administer the cells.
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FIG. 8. Treatment with exosomes does not alter
the lesion size after traumatic brain injury
(TBI). Exo-empty and Exo-17-92 treatments
administered intravenously 24 h after TBI do not
signiﬁcantly alter the cortical lesion volume
measured 35 days after TBI compared with
Vehicle treatment. Scale bars = 3 mm. Quantitative
data shown in bar graph represent
mean – standard deviation. N = 8/group. Color
image is available online.

Accumulating studies have shown that engineered
exosomes enriched with specific miRNAs play an important role in repairing damaged tissues including brain
injury.12,13,23,58 For example, compared with naive MSCexosomes, our previous studies show that engineered
MSC-exosomes carrying elevated levels of the miR-1792 cluster further enhance axonal growth in cultured cortical neurons,28 enhance axon-myelin remodeling and
motor electrophysiological recovery after stroke,59 and increase neural plasticity and functional recovery after stroke
in rats.29 Although TBI and stroke share similar pathophysiology including cell injury, BBB breakdown, apoptosis, neuroinflammation, white matter injury, and brain
atrophy, the fact that these injuries arise from different
types of primary insults leads to diverse cellular vulnerability patterns as well as a spectrum of injury processes.60
Ours is the first study demonstrating the therapeutic efficacy of miR-17-92 cluster-enriched MSC-derived exosomes in TBI. Our data in this study further confirm
that selective manipulation of expression of miR-17-92
in the parent MSCs leads to an enhanced therapeutic efficacy of their harvested exosomes carrying an elevated
level of miR-17-92 in a rat model of TBI.
Neuroinflammation is a key component of the secondary injury cascades after TBI.61–64 Pre-clinical studies
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indicate that post-traumatic persistent and progressive
neuroinflammation is associated with neurodegeneration
that may be treatable long after the original brain injury.64
In the present study, treatment with miR-17-92 clusterenriched exosomes significantly reduced the number of
GFAP+ astrocytes and CD68+ microglia/macrophages
compared with the Exo-empty. Anti-inflammatory effects
of exosomes are similar to those found after MSC therapy
in animal models of stroke65,66 and TBI.67
Microglia constantly survey the surrounding parenchyma and respond rapidly to sustain neuronal health
by releasing cytokines, free radicals, antioxidants, and
neurotrophic factors.68
Astrocytes are actively involved in neurogenesis, synaptogenesis, angiogenesis, BBB repair, and glial scar
formation after TBI.69 Astrocytes also play an important
role in the brain waste clearance via the glymphatic system after TBI.70,71 Prolonged activation of astrocytes and
microglia contribute to brain damage and functional deficits after TBI.64 Astrocytes and microglia play dual roles
in mediating brain damage and repair where beneficial
and the detrimental aspects of their cellular responses determine the extent of damage and subsequent repair.72
Our data also support that suppression of activated
microglia/macrophages with exosome treatment contributes to increased angiogenesis and neurogenesis, and subsequent improvement in functional recovery after TBI.
This is in agreement with a recent study that shows
human adipose MSC-derived exosomes administered
intracerebroventricularly 24 h post-injury suppress activation of microglia/macrophages, inhibit inflammation,
and facilitate functional recovery in rats after TBI.73
Interestingly, we have also shown that exosomes harvested from miR-133b-overexpressing MSCs can stimulate secondary release of neurite-promoting exosomes
from endogenous astrocytes, which is associated with improved neural plasticity and functional recovery after
stroke.74 These findings suggest that treatment with select
miRNA-enriched exosomes can promote additional exosome release from endogenous astrocytes (likely from
other neural cells), which may amplify the therapeutic
effects of exogenous exosome treatment.
New neurons are generated from neural stem/progenitor cells in mammals during adulthood and after select
neurological disorders, and thus neurogenesis may be a
potential target area for treatments.75 Angiogenesis and
neurogenesis coordinately interact with each other in
the developing and adult brain, during which they share
a common post-transcriptional regulator, the miR-17-92
cluster.76 The generation of new vasculature facilitates
highly coupled neurorestorative processes including neurogenesis and synaptogenesis, which in turn lead to
improved functional recovery in TBI.77 The miR-17-92
cluster modulates proliferation of neural progenitor
cells during development and during neurological
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disorders such as stroke, and the miR-17-92 cluster in endothelial cells regulates angiogenesis during embryonic
stage and adulthood.34,78
Our recent study demonstrated that ablation of the
miR-17-92 cluster in neural stem cells (NSC) significantly reduces the number of proliferating NSCs and neuroblasts and neuronal differentiation in the DG of the
hippocampus and significantly impairs hippocampaldependent learning and memory measured by social recognition memory, novel object recognition, and MWM
tests.78 A highly significant correlation exists between reduction in newly generated neuroblasts in the DG and
cognition deficits in miR-17-92 knockout mice.78
Our TBI data indicate that miR-17-92 cluster-enriched
exosomes increase angiogenesis and neurogenesis in the
DG that are associated with enhanced improvement in spatial learning and memory after brain injury, compared with
Exo-empty. This is consistent with our previous study that
the miR-17-92 cluster mediates adult NSC proliferation
and survival in the subventricular zone after stroke.79
Our data indicate that increase of the miR-17-92 cluster amplifies endogenous neurogenesis in ischemic and
traumatic injured brains. Our recent study demonstrates
that miR-17-92 enriched exosomes derived from MSCs
enhance axon-myelin remodeling and motor electrophysiological recovery after stroke.59 The roles of the miR17-92 cluster in neuronal and vascular plasticity make
miR-17-92 cluster-enriched exosomes a promising regenerative treatment to enhance brain tissue repair and
functional recovery after brain injury.
Our previous proof-of-principle study demonstrated that
CD63-GFP-tagged exosomes derived from MSCs were
taken up by neurons and astrocytes of the injured brains
measured 30 min after IV administration in rats with
TBI.12 Although whether treatment with miR-17-92enriched exosomes increases levels of miR-17-92 in the
brain was not determined in the present study, our recent
work demonstrated that IV administration of miR-17-92
cluster-enriched MSC exosomes enhanced neurofunctional recovery of stroke, which may be mediated in part
via the activation of the PI3K/protein kinase B/mechanistic target of rapamycin/glycogen synthase kinase 3 beta
signaling pathway induced by the downregulation of phosphatase and tensin homolog (PTEN).29,59 The PTEN is
among the first validated miR-17-92 cluster targets.80,81
Emerging evidence has implicated miR-17-92 cluster
as a master regulator of neurogenesis.81
Our recent study demonstrated that conditional knockout
of the miR-17-92 cluster in neural stem cells (NSCs) significantly increases cytoskeleton-associated protein, Enigma
homolog 1 (ENH1) and reduces its downstream transcription factor, inhibitor of differentiation 1 (ID1), as well as increases PTEN gene expression.78 These proteins are related
to neuronal differentiation.78 The MiR-17-92 cluster
knockdown mice have diminished hippocampal neurogen-
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esis and impaired cognitive function.78 These data indicate
that the miR-17-92 cluster in NSCs is critical for normal
cognitive and behavioral function via targeting ENH1/
ID1 and regulating neurogenesis in adult mice.
Further studies are warranted to investigate (1)
whether miR-17-92 cluster-enriched exosomes regulate
these signaling pathways for improving tissue and functional recovery in TBI; and (2) whether treatment with
miR-17-92-enriched exosomes increases levels of miR17-92 and decreases expression levels of their mRNA
targets in the injured brain.
In this study, miR-17-92 cluster-enriched exosomes
were generated from human MSCs transfected with a
miR-17-92 cluster plasmid. Quantitative RT-PCR analysis of the harvested exosomes showed that levels of all
individual six members (miR-17, 18a, 19a, 19b, 20a,
92) of the miR-17-92 cluster were increased severalfold within exosomes isolated from MSCs transfected
with the miR-17-92 cluster (Exo-17-92) compared with
their levels within exosomes from MSCs transfected
with the empty vector (Exo-empty).
Cellular miRNA levels can also be increased by delivering miRNA mimics (agomir) or decreased by anti-miR
(antagomir) to regulate native microRNA functions in
recipient cells.26 Several miRNA mimics, including
miR-23a, miR-27a, miR-21, miR-23b and miR-124-3p
mimics, have been demonstrated to exert neuroprotection
and anti-inflammation against brain damage and improve
neurological functional recovery in animal models of
TBI.26,82 Some antagomirs have also been found to exhibit protective effects against TBI. Suppression of select
miRNAs such as miR-193a,83 miR-144,84 miR-155,85
miR-71186 with corresponding antagomirs improves neurological function recovery in animal models of TBI
through antineuroinflammation, reduction in lesion volume, cell loss, and brain edema.
Regulation of miRNA is promising for management of
TBI. Naked miRNA, agomir, and antagomir are vulnerable to nuclease degradation before reaching the target
cells. Viral and nonviral vector systems are used for delivery of miRNA, agomir, and antagomir into the cells.
There are safety concerns for bioactive viruses because
of the immunogenicity and the risk of triggering an oncogenic transformation by viruses as well as their innate
immunity and antigen specific adaptive immune responses leading to reduced efficiency of gene transfer.87
Exosomes have emerged as an effective nonviral
delivery system for miRNAs. The miRNA and their
mimics/inhibitors can be loaded by different methods
including transfection or electroporation into isolated
exosomes.87 Exosomes have unique advantages over
other vectors for gene delivery including: (1) exosomes
are a cell-free natural system for carrying miRNA to
mediate intercellular communications, (2) exosomal membranes protect the miRNA from digestion by extracellular
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nuclease before they reach recipient cells, and (3) exosomes can cross the BBB and are rapidly taken up by target cells.12,13,23,64,88 These advantages make them a more
efficient vehicle for gene delivery.
Our data demonstrate that empty exosomes as the negative control for miR-17-92-enriched exosomes also led
to significant improvements in functional recovery, reduction in neuroinflammation and hippocampal neuronal
cell loss, promotion in angiogenesis and neurogenesis
compared with the saline treatment. These beneficial effects suggest that this control treatment possessed some
therapeutic substances.
As shown in Supplementary Data Fig. S1C, low levels
of miR-17-92 were detected in the Exo-empty although
individual levels of miR-17-92-cluster in the Exo-17-92
were significantly higher (in the range of 2–11 times dependent on the individual miRNA member) than those
in Exo-empty. The low levels of miR-17-92 cluster
may contribute to the beneficial effects of Exo-empty,
which are consistent with our recent studies demonstrating that compared with treatment controls, the empty
exosomes significantly improved functional recovery
in stroke rats while the miR-17-92-enriched exosomes
further enhanced functional recovery.29,59 In addition,
increasing evidence indicates that other miRNAs and
cargoes (mRNAs, proteins, lipids) in exosomes also
play an important role in the cell-cell communication
and may contribute to therapeutic effects in the exosome
treatment for TBI12,13,89 that we did not investigate in the
present study.
The MiRNA-enriched exosomes from other cell
sources have shown beneficial effects for management
of TBI. For example, IV injection of miR-124-3penriched exosomes derived from microglia reveals that
exosomal miR-124-3p is associated with a decrease in
the modified mNSS score and improvement in MWM
test results in mice with repetitive TBI via inhibiting
neuronal autophagy.90 It is important to determine
whether a combined approach of using exosomes with
overexpression or deletion of the select miRNAs have
additive or synergistic effects for management of TBI
and other neurological disease. In addition to exosomes,
MSCs also release other extracellular vesicles and soluble factors, which may contribute to therapeutic effects
underlying MSC therapy and can be developed for management of TBI.53,54
In eukaryotic cells, miRNAs constitute a major regulatory gene family, and different cell types and tissues
express different sets of miRNAs.91–93 Although the
enriched miR-17-92 enhances the therapeutic benefit,
we do not exclude a therapeutic contribution of other miRNAs, RNAs, proteins for management of TBI. In this
study, a single dose of miR-17-92 cluster-enriched exosomes was administered 24 h in TBI rats. It is unknown,
however, whether the administration of exosomes

1547

enriched with miR-17-92 cluster at the early or later
stages or repeated treatments could result in a more effective tissue and functional recovery after TBI. Further
investigation of these questions will make the application of these exosomes more translational in the management of TBI.
In the present study, we only evaluated therapeutic
effects of exosomes in the moderate TBI model. We selected this moderate TBI rat model based on our previous
studies that have demonstrated significant therapeutic effects of MSCs and naive exosomes for treatment of moderate TBI in rats.5,19,37 In addition to beneficial effects of
exosome treatment in moderate TBI, our recent study further demonstrated that naı̈ve exosomes derived from
human MSCs had beneficial effects in a swine model of
severe TBI and hemorrhagic shock.21
A recent study demonstrated that IV injected microglial
exosomes enriched with miR-124-3p were taken up by
neurons in injured brain, improved the cognitive outcome
in mice after repetitive mild TBI.94 These findings indicate that both naı̈ve exosomes and tailored exosomes
overexpressing select cargos including miRNAs may
hold a therapeutic potential for management of mild,
moderate, and severe TBI.
Conclusions
We demonstrate that IV administration of exosomes engineered to enrich the miR-17-92 cluster significantly
reduces neuroinflammation and neuronal cell loss, increases
neurogenesis and angiogenesis, and significantly augments
the therapeutic benefits on functional recovery for TBI compared with the Exo-empty. Contents in exosomes can be
engineered to amplify neural plasticity and enhance functional recovery in TBI. The MSC-derived exosomes
enriched with select miRNA may serve as an effective
and possibly superior surrogate for stem cell therapy for
neural injury or disease.
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